The PRISM trial interim data showed an 89% reduction in the annualized injection rate with the 3E10 vg/eye dose of 4D-150. Can you discuss the significance of this reduction for patients' quality of life and overall disease management?

With a +4.2 letter improvement in mean best corrected visual acuity (BCVA) at the 3E10 vg/eye dose, how does this outcome compare to existing treatments for wet AMD? What implications does this have for the long-term visual prognosis of patients?

The trial results highlighted sustained and greater anatomic control without fluctuations at the 3E10 vg/eye dose. Can you explain how this stability impacts retinal health and the progression of wet AMD?

No significant inflammation was reported in patients treated with the 3E10 vg/eye dose and topical corticosteroid regimen. How does this safety profile compare with current anti-VEGF treatments, and what advantages does it offer to patients?

The Phase 1 long-term follow-up data indicated that patients remained injection-free for up to 2.5 years. How important is this finding for the future of gene therapy treatments in ophthalmology?

4D-150 is being developed for wet AMD, diabetic macular edema (DME), and diabetic retinopathy (DR). Do you see potential for this treatment across these different ophthalmic conditions?

Given the broad range of disease activity and prior anti-VEGF treatment in the PRISM trial cohort, how can patient selection be optimized for 4D-150 treatment to maximize efficacy and safety?

With Phase 3 clinical trial planning ongoing and expected initiation in Q1 2025, what are your expectations for the next stages of 4D-150’s development, and how might this impact the treatment landscape for wet AMD?